P140 Updates27 May 2026 21:10
So had a quick refresh, excluding the podcasts I might add (those were quite funny). Does the below look like moving goal post and blue changes in narrative, or am I just a cynic.
23rd October
Further updates, as appropriate, will be communicated to the market between now and our stated objective of completing a deal by the end of 2025.
24th November
To this end, based on the engagements with potential partners to date, the Board now expects the completion of any partnership deal to extend beyond the end of 2025, with our aim being to move to completion of a deal as soon as practicable in 2026.
17th March
At the same time, I would like to reassure shareholders that P140 remains a core value driver for ImmuPharma. We continue to make good progress in detailed discussions with a number of potential partners and remain focused on completing a value‑enhancing licensing deal in 2026."
27th May
Active discussions continue with a number of potential global commercial partners for P140, with the Company focused on completing a value-enhancing licensing transaction in 2026